Rudy Li
Stock Analyst at Wolfe Research
(5.00)
# 18
Out of 5,182 analysts
40
Total ratings
78.38%
Success rate
109.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Peer Perform | n/a | $39.46 | - | 6 | Mar 31, 2026 | |
| ALKS Alkermes | Initiates: Outperform | $45 | $34.14 | +31.81% | 1 | Feb 24, 2026 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $230 | $185.00 | +24.32% | 1 | Feb 24, 2026 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $60 | $54.53 | +10.03% | 5 | Feb 24, 2026 | |
| STOK Stoke Therapeutics | Initiates: Outperform | $40 | $33.33 | +20.01% | 5 | Feb 24, 2026 | |
| QURE uniQure | Initiates: Peer Perform | n/a | $18.05 | - | 1 | Feb 24, 2026 | |
| DNLI Denali Therapeutics | Initiates: Peer Perform | n/a | $20.06 | - | 1 | Feb 24, 2026 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $500 | $321.92 | +55.32% | 4 | Feb 24, 2026 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $160 | $128.12 | +24.88% | 1 | Feb 24, 2026 | |
| DFTX Definium Therapeutics | Initiates: Outperform | $25 | $21.27 | +17.54% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $22.67 | +45.57% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $88.99 | -10.10% | 3 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $10.75 | +179.07% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $24.47 | -38.70% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.88 | +4,450.63% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $11.51 | +56.39% | 7 | Aug 28, 2025 |
Centessa Pharmaceuticals
Mar 31, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $39.46
Upside: -
Alkermes
Feb 24, 2026
Initiates: Outperform
Price Target: $45
Current: $34.14
Upside: +31.81%
Axsome Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $230
Current: $185.00
Upside: +24.32%
Xenon Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $60
Current: $54.53
Upside: +10.03%
Stoke Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $33.33
Upside: +20.01%
uniQure
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $18.05
Upside: -
Denali Therapeutics
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $20.06
Upside: -
Praxis Precision Medicines
Feb 24, 2026
Initiates: Outperform
Price Target: $500
Current: $321.92
Upside: +55.32%
Neurocrine Biosciences
Feb 24, 2026
Initiates: Outperform
Price Target: $160
Current: $128.12
Upside: +24.88%
Definium Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $25
Current: $21.27
Upside: +17.54%
Feb 24, 2026
Initiates: Outperform
Price Target: $33
Current: $22.67
Upside: +45.57%
Jan 2, 2026
Maintains: Buy
Price Target: $80
Current: $88.99
Upside: -10.10%
Sep 29, 2025
Initiates: Buy
Price Target: $30
Current: $10.75
Upside: +179.07%
Sep 29, 2025
Initiates: Buy
Price Target: $15
Current: $24.47
Upside: -38.70%
Sep 29, 2025
Initiates: Buy
Price Target: $40
Current: $0.88
Upside: +4,450.63%
Aug 28, 2025
Maintains: Buy
Price Target: $18
Current: $11.51
Upside: +56.39%